Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity

碩士 === 國立陽明大學 === 醫學生物技術研究所 === 94 === Previous studies have shown that chemotherapy causes deamidation of the protein Bcl-xL in tumor cells. This Bcl-xL deamidation inhibits its antiapoptotic ability and sensitizes tumor cells to cisplatin treatment. Surprisingly, Rb inhibits this process. To test...

Full description

Bibliographic Details
Main Authors: Wei-Ting Cheng, 鄭瑋婷
Other Authors: I-Tsuen Chen
Format: Others
Language:zh-TW
Published: 2006
Online Access:http://ndltd.ncl.edu.tw/handle/99220643720983262007
id ndltd-TW-094YM005604014
record_format oai_dc
spelling ndltd-TW-094YM0056040142015-10-13T16:31:16Z http://ndltd.ncl.edu.tw/handle/99220643720983262007 Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity Bcl-xL去醯胺基化與癌細胞對Cisplatin的敏感性呈正相關 Wei-Ting Cheng 鄭瑋婷 碩士 國立陽明大學 醫學生物技術研究所 94 Previous studies have shown that chemotherapy causes deamidation of the protein Bcl-xL in tumor cells. This Bcl-xL deamidation inhibits its antiapoptotic ability and sensitizes tumor cells to cisplatin treatment. Surprisingly, Rb inhibits this process. To test this model, we have shown recently that E1A-mediated Rb inactivation in an ovarian cancer cell line (SKOV3.ip1) leads to Bcl-xL deamidation which contributes to cisplatin-induced apoptosis. Furthermore, ectopic expression of deamidated form of Bcl-xL (N52/66D) enhances cell death, whereas the nondeamidated Bcl-xL (N52/66A) protects E1A-mediated apoptosis. In this follow-up studies, we showed that BH3 protein bad interacts equally well with all three forms of Bcl-xL protein. In addition, ectopic expression of p53 did not enhance cell death or Bcl-xL deamidation in SKOV3.ip1. To test whether Bcl-xL deamidation occurs in other cancer cells, we selected four cancer cell lines with various Rb and p53 status. Our data show that the cell lines sensitive to cisplatin correlated with induction of Bcl-xL deamidation, whereas the cell lines resistant to cisplatin exhibited no induction of Bcl-xL deamidation. Interestingly, expression of E1A did not sensitize the cisplatin-resistant cell lines or Bcl-xL deamidation. Both the cisplatin-resistant cell lines are Rb wt. Furthermore, In vitro alkaline treatment induced Bcl-xL deamidation in these cell lines, suggesting that no induction of Bcl-xL deamidation in the cisplatin- resistant cell lines is not due to mutation of Bcl-xL at 55 and 66 residues. We also noticed that level of Bcl-2 was higher in the cisplatin-resistant cells than in the cisplatin-sensitive cells. Moreover, we found that N-acetylcysteine protected cells from cisplatin induced apoptosis and repressed Bcl-xL deamidation. This suggested that reactive oxygen species (ROS) may be involved in the induction of Bcl-xL deamidation by cisplatin. I-Tsuen Chen 陳一村 2006 學位論文 ; thesis 73 zh-TW
collection NDLTD
language zh-TW
format Others
sources NDLTD
description 碩士 === 國立陽明大學 === 醫學生物技術研究所 === 94 === Previous studies have shown that chemotherapy causes deamidation of the protein Bcl-xL in tumor cells. This Bcl-xL deamidation inhibits its antiapoptotic ability and sensitizes tumor cells to cisplatin treatment. Surprisingly, Rb inhibits this process. To test this model, we have shown recently that E1A-mediated Rb inactivation in an ovarian cancer cell line (SKOV3.ip1) leads to Bcl-xL deamidation which contributes to cisplatin-induced apoptosis. Furthermore, ectopic expression of deamidated form of Bcl-xL (N52/66D) enhances cell death, whereas the nondeamidated Bcl-xL (N52/66A) protects E1A-mediated apoptosis. In this follow-up studies, we showed that BH3 protein bad interacts equally well with all three forms of Bcl-xL protein. In addition, ectopic expression of p53 did not enhance cell death or Bcl-xL deamidation in SKOV3.ip1. To test whether Bcl-xL deamidation occurs in other cancer cells, we selected four cancer cell lines with various Rb and p53 status. Our data show that the cell lines sensitive to cisplatin correlated with induction of Bcl-xL deamidation, whereas the cell lines resistant to cisplatin exhibited no induction of Bcl-xL deamidation. Interestingly, expression of E1A did not sensitize the cisplatin-resistant cell lines or Bcl-xL deamidation. Both the cisplatin-resistant cell lines are Rb wt. Furthermore, In vitro alkaline treatment induced Bcl-xL deamidation in these cell lines, suggesting that no induction of Bcl-xL deamidation in the cisplatin- resistant cell lines is not due to mutation of Bcl-xL at 55 and 66 residues. We also noticed that level of Bcl-2 was higher in the cisplatin-resistant cells than in the cisplatin-sensitive cells. Moreover, we found that N-acetylcysteine protected cells from cisplatin induced apoptosis and repressed Bcl-xL deamidation. This suggested that reactive oxygen species (ROS) may be involved in the induction of Bcl-xL deamidation by cisplatin.
author2 I-Tsuen Chen
author_facet I-Tsuen Chen
Wei-Ting Cheng
鄭瑋婷
author Wei-Ting Cheng
鄭瑋婷
spellingShingle Wei-Ting Cheng
鄭瑋婷
Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
author_sort Wei-Ting Cheng
title Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
title_short Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
title_full Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
title_fullStr Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
title_full_unstemmed Bcl-xL Deamidation of Cancer Cells Correlates with Cisplatin-induced Cytotoxicity
title_sort bcl-xl deamidation of cancer cells correlates with cisplatin-induced cytotoxicity
publishDate 2006
url http://ndltd.ncl.edu.tw/handle/99220643720983262007
work_keys_str_mv AT weitingcheng bclxldeamidationofcancercellscorrelateswithcisplatininducedcytotoxicity
AT zhèngwěitíng bclxldeamidationofcancercellscorrelateswithcisplatininducedcytotoxicity
AT weitingcheng bclxlqùxīànjīhuàyǔáixìbāoduìcisplatindemǐngǎnxìngchéngzhèngxiāngguān
AT zhèngwěitíng bclxlqùxīànjīhuàyǔáixìbāoduìcisplatindemǐngǎnxìngchéngzhèngxiāngguān
_version_ 1717771910860767232